🔴 Nyxoah is trading 8.1% down in pre-market

Nyxoah is trading 8.1% lower at $1.02 pre-market; the catalyst is unclear.

• No new company-specific announcement surfaced in the search for the October 19 move.
• The October 15 release reported 12-month ACCCESS results and an FDA supplement submission; it predates the alert and does not explain the decline.
• Major U.S. indices were higher; Nyxoah fell in each of the prior three sessions. A previously reported proposed $50 million at-the-market offering could raise dilution concerns, but its connection is unconfirmed.